credit-freepik

Study by Mass General Brigham explores a link between diabetes drugs and reduced kidney stone risk.

credit-freepik

Kidney stones on the rise worldwide, especially in individuals with Type 2 diabetes.

credit-freepik

SGLT2 inhibitors show promise in lowering the likelihood of kidney stone development.

credit-freepik

Data from 716,406 adults with Type 2 diabetes analyzed in a comprehensive study published in JAMA Internal Medicine.

credit-freepik

Individuals starting SGLT2 inhibitors have a 30% lower risk of kidney stones compared to GLP1 agonists.

credit-freepik

Consistent findings across various demographics highlight potential universal applicability.

credit-freepik

Brigham and Women's Hospital and Massachusetts General Hospital researchers jointly conduct the groundbreaking investigation.

credit-freepik

Dr. Julie Paik underscores the study's potential impact on clinical decision-making for diabetic patients at risk of kidney stones.

credit-freepik

Consistency in outcomes offers hope for diverse patient groups, irrespective of sex, race, chronic kidney disease history, or obesity.

credit-freepik

Research unveils key link between SGLT2 inhibitors and renal health, heralding transformative potential for global diabetic patient care